Endogenous and exogenous nitrates and their role in myocardial ischaemia - PubMed (original) (raw)

Review

Endogenous and exogenous nitrates and their role in myocardial ischaemia

T F Lüscher. Br J Clin Pharmacol. 1992.

Abstract

1. Although nitrates have been prescribed in patients with angina pectoris for more than a century, their mechanism of action has only been understood recently. 2. The discovery of the endogenous nitrovasodilator nitric oxide, which is formed in endothelial cells by the enzyme nitric oxide synthase, has greatly expanded our knowledge. Nitric oxide, if released from endothelial cells can interact with vascular smooth muscle as well as circulating blood cells such as platelets. Nitric oxide activates soluble guanylate cyclase, which in turn leads to an intracellular increase in cyclic GMP. In vascular smooth muscle, this causes vasorelaxation, in platelets dysaggregation and prevention of platelet adhesion. This protective pathway both reduces the effects of vasoconstrictor substances, can produce profound vasodilation, if activated appropriately and acts as a regulator of platelet-vessel wall interaction. In addition, nitric oxide inhibits the production and action of endothelin, a 21 amino acid vasoconstrictor peptide formed by endothelial cells. 3. Exogenous nitrovasodilators also exert their action by releasing nitric oxide from the molecule. Their action is particularly pronounced in blood vessels with a low basal production of nitric oxide and is enhanced after removal of the endothelium. In coronary artery disease, the formation of endothelium-derived nitric oxide is reduced, its breakdown is increased, but only at later stages, is the action of endogenous and therapeutic nitrates depressed. 4. Hence, nitrates are an appropriate therapeutic tool in patients with coronary artery disease to substitute the effects of the impaired activity of the endothelial L-arginine/nitric oxide pathway.

PubMed Disclaimer

Cited by

Biological targets for isatin and its analogues: Implications for therapy.
Medvedev A, Buneeva O, Glover V. Medvedev A, et al. Biologics. 2007 Jun;1(2):151-62. Biologics. 2007. PMID: 19707325 Free PMC article.
Physiological stress increases renal injury in eNOS-knockout mice.
Pointer MA, Daumerie G, Bridges L, Yancey S, Howard K, Davis W, Huang P, Loscalzo J. Pointer MA, et al. Hypertens Res. 2012 Mar;35(3):318-24. doi: 10.1038/hr.2011.185. Epub 2011 Dec 15. Hypertens Res. 2012. PMID: 22170389 Free PMC article.
Nitric oxide in heart failure: friend or foe.
Jugdutt BI. Jugdutt BI. Heart Fail Rev. 2002 Oct;7(4):385-9. doi: 10.1023/a:1020767731450. Heart Fail Rev. 2002. PMID: 12379823
Regulation of platelet granule exocytosis by S-nitrosylation.
Morrell CN, Matsushita K, Chiles K, Scharpf RB, Yamakuchi M, Mason RJ, Bergmeier W, Mankowski JL, Baldwin WM 3rd, Faraday N, Lowenstein CJ. Morrell CN, et al. Proc Natl Acad Sci U S A. 2005 Mar 8;102(10):3782-7. doi: 10.1073/pnas.0408310102. Epub 2005 Feb 28. Proc Natl Acad Sci U S A. 2005. PMID: 15738422 Free PMC article.
Human endothelial dysfunction: EDCFs.
Virdis A, Ghiadoni L, Taddei S. Virdis A, et al. Pflugers Arch. 2010 May;459(6):1015-23. doi: 10.1007/s00424-009-0783-7. Epub 2010 Jan 27. Pflugers Arch. 2010. PMID: 20107832 Review.

References

1. J Cardiovasc Pharmacol. 1989;14 Suppl 11:S86-90 - PubMed
1. Br J Pharmacol. 1987 Nov;92(3):639-46 - PubMed
1. Lancet. 1991 Apr 20;337(8747):939-43 - PubMed
1. Eur J Pharmacol. 1987 Jul 2;139(1):19-30 - PubMed
1. N Engl J Med. 1986 Feb 20;314(8):488-500 - PubMed

Endogenous and exogenous nitrates and their role in myocardial ischaemia - PubMed (original) (raw)